Does AXITINIB Cause Hypertransaminasaemia? 21 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 21 reports of Hypertransaminasaemia have been filed in association with AXITINIB (INLYTA). This represents 0.1% of all adverse event reports for AXITINIB.
21
Reports of Hypertransaminasaemia with AXITINIB
0.1%
of all AXITINIB reports
0
Deaths
7
Hospitalizations
How Dangerous Is Hypertransaminasaemia From AXITINIB?
Of the 21 reports, 7 (33.3%) required hospitalization, and 2 (9.5%) were considered life-threatening.
Is Hypertransaminasaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for AXITINIB. However, 21 reports have been filed with the FAERS database.
What Other Side Effects Does AXITINIB Cause?
Death (2,222)
Diarrhoea (2,187)
Fatigue (1,816)
Neoplasm progression (1,315)
Hypertension (1,146)
Off label use (1,075)
Nausea (955)
Decreased appetite (920)
Dysphonia (871)
Disease progression (768)
What Other Drugs Cause Hypertransaminasaemia?
METHOTREXATE (436)
ACETAMINOPHEN (326)
PACLITAXEL (318)
CARBOPLATIN (304)
PEMBROLIZUMAB (231)
ATORVASTATIN (207)
CYCLOPHOSPHAMIDE (202)
PREDNISONE (198)
GEMCITABINE (196)
DEXAMETHASONE (169)
Which AXITINIB Alternatives Have Lower Hypertransaminasaemia Risk?
AXITINIB vs AZACITIDINE
AXITINIB vs AZATHIOPRINE
AXITINIB vs AZD-1222
AXITINIB vs AZELAIC ACID
AXITINIB vs AZELASTINE